Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected with Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

Clinical Infectious Diseases

Volumn 65, Issue 1, 2017, Pages 6-12

  Wyles, David ^a   Braü, Norbert ^b,c   Kottilil, Shyam ^d   Daar, Eric S ^e   Ruane, Peter ^f   Workowski, Kimberly ^g   Luetkemeyer, Anne ^h   Adeyemi, Oluwatoyin ⁱ   Kim, Arthur Y ^j   Doehle, Brian ^k   Huang, K C ^k   Mogalian, Erik ^k   Osinusi, Anu ^k   McNally, John ^k   Brainard, DIana M ^k   McHutchison, John G ^k   Naggie, Susanna ^l   Sulkowski, Mark ^m  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e HARBOR UCLA MEDICAL CENTER   (United States)

^f Ruane Medical and Liver Health Institute   (United States)

^g EMORY UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k GILEAD SCIENCES   (United States)

^l DUKE UNIVERSITY   (United States)

^m JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

ASTRAL 5; HCV HIV coinfection; hepatitis C virus; sofosbuvir; velpatasvir

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COBICISTAT; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SOFOSBUVIR PLUS VELPATASVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; SOFOSBUVIR; VELPATASVIR;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL OUTCOME; COMPENSATED LIVER CIRRHOSIS; DIARRHEA; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIAL NERVE PALSY; SEPSIS; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; CLINICAL TRIAL; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; UNITED STATES;

ADULT; AGED; ANTIVIRAL AGENTS; CARBAMATES; COINFECTION; FEMALE; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SOFOSBUVIR; UNITED STATES;

EID: 85021798989     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix260     Document Type: Article

References (22)

1. Peters L, Klein MB. Epidemiology of hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS 2015; 10:297-302.
2. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44(1 suppl):S6-9.
3. Martín-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: A European collaborative study. Clin Infect Dis 2004; 38:128-33.
4. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-8.
5. Price JC, Thio CL. Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol 2010; 8:1002-12.
6. Menard A, Colson P, Catherine D, et al. First real life evidence of new direct-acting antivirals (DAA) in co-infected HIV HCV patients: Better than ever. Clin Infect Dis 2016; 62:947-9.
7. Wyles DL, Ruane PJ, Sulkowski MS, et al; ALLY-2 Investigators. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:714-25.
8. Naggie S, Cooper C, Saag M, et al; ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:705-13.
9. American Association for the Study of Liver Diseases/Infectious Diseases Society of America. Recommendations for testing, managing, treating hepatitis C. Available at: Http://www. hcvguidelines. org. Accessed 15 September 2016.
10. Cheng G, Yu M, Peng B, et al. GS-5816: A second generation HCV NS5A inhibitor with potent antiviral activity, board genotypic coverage and a high resistance barrier. In: 48th Annual Meeting of the European Association for the Study of the Liver, Amsterdam, Netherlands, 24-28 April 2013. Abstract 1191.
11. Gilead Sciences. Epclusa (sofosbuvir and velpatasvir) tablets: US prescribing information. Available at: Www. gilead. com/~/media/Files/pdfs/medicines/liver-disease/epclusa/epclusa-pi. pdf. Accessed 15 September 2016.
12. Feld JJ, Jacobson IM, Hézode C, et al; ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, 6 infection. N Engl J Med 2015; 373:2599-607.
13. Foster GR, Afdhal N, Roberts SK, et al; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373:2608-17.
14. Curry MP, O'Leary JG, Bzowej N, et al; ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373:2618-28.
15. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2016. doi:10. 1016/j. jhep. 2016. 09. 001.
16. Mogalian E, Stamm L, Osinusi A, et al. Drug-drug interaction studies between hepatitis C virus antivirals sofosbuvir and velpatasvir and HIV antiretroviral therapies. In: The Liver Meeting, American Association for the Study of Liver Diseases, San Francisco, CA, 13-17 November 2015. Abstract 2265
17. Mogalian E, Stamm L, Osinusi A, et al. Drug interaction studies between sofosbuvir/velpatasvir and boosted HIV ARV regimens. In: 23rd Conference on Retroviruses and Opportunistic Infections, Boston, MA, 22-25 February 2016. Abstract 100.
18. Custodio JM, Jin F, Gibiansky L, et al. Evaluation of tenofovir alafenamide pharmacokinetics: No influence of demographic or HIV disease factors. In: European AIDS Conference, Barcelona, Spain, 21-24 October 2015. Poster PE10/14.
19. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology 2016; 151:501-12. e1.
20. Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection. In: The Liver Meeting, American Association for the Study of Liver Diseases, San Francisco, CA, 13-17 November 2015. Abstract LB-22.
21. Zeuzem S, Mizokami M, Pianko S, et al. Prevalence of pre-treatment NS5A resistance associated variants in genotype 1 patients across different regions using deep sequencing and effect on treatment outcome with LDV/SOF. In: The Liver Meeting, American Association for the Study of Liver Diseases, San Francisco, CA, 13-17 November 2015. Abstract 91.
22. German P, Garrison K, Pang PS, et al. Drug-drug interactions between anti-HCV regimen ledipasvir/sofosbuvir and antiretrovirals. Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 23-26 February 2015. Abstract 82.